113 related articles for article (PubMed ID: 38593916)
1. Development and in-depth characterization of BRAFi-resistant melanoma cell lines in vitro and in vivo.
Saraswat A; Patel K
Exp Cell Res; 2024 May; 438(1):114033. PubMed ID: 38593916
[TBL] [Abstract][Full Text] [Related]
2. Reversing vemurafenib-resistance in primary melanoma cells by combined romidepsin and type I IFN treatment through blocking of tumorigenic signals and induction of immunogenic effects.
Fragale A; Stellacci E; Romagnoli G; Licursi V; Parlato S; Canini I; Remedi G; Buoncervello M; Matarrese P; Pedace L; Ascione B; Pizzi S; Tartaglia M; D'Atri S; Presutti C; Capone I; Gabriele L
Int J Cancer; 2023 Sep; 153(5):1080-1095. PubMed ID: 37293858
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of USP14 enhances anti-tumor effect in vemurafenib-resistant melanoma by regulation of Skp2.
Wu T; Li C; Zhou C; Niu X; Li G; Zhou Y; Gu X; Cui H
Cell Biol Toxicol; 2023 Oct; 39(5):2381-2399. PubMed ID: 35648318
[TBL] [Abstract][Full Text] [Related]
4. Sestrin2 contributes to BRAF inhibitor resistance via reducing redox vulnerability of melanoma cells.
Guo S; Yue Q; Wang S; Wang H; Ye Z; Zhang W; Shi Q; Gao T; Li C; Zhu G
J Dermatol Sci; 2023 Feb; 109(2):52-60. PubMed ID: 36858850
[TBL] [Abstract][Full Text] [Related]
5. Silencing FOXP2 reverses vemurafenib resistance in BRAF
Jiang S; Huang Y; Li Y; Gu Q; Jiang C; Tao X; Sun J
Endocrine; 2023 Jan; 79(1):86-97. PubMed ID: 36331719
[TBL] [Abstract][Full Text] [Related]
6. Targeting ER stress-induced autophagy overcomes BRAF inhibitor resistance in melanoma.
Ma XH; Piao SF; Dey S; McAfee Q; Karakousis G; Villanueva J; Hart LS; Levi S; Hu J; Zhang G; Lazova R; Klump V; Pawelek JM; Xu X; Xu W; Schuchter LM; Davies MA; Herlyn M; Winkler J; Koumenis C; Amaravadi RK
J Clin Invest; 2014 Mar; 124(3):1406-17. PubMed ID: 24569374
[TBL] [Abstract][Full Text] [Related]
7. The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma.
Cui H; Wang Q; Miller DD; Li W
Front Pharmacol; 2021; 12():637098. PubMed ID: 33841154
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma models.
Smyth T; Paraiso KHT; Hearn K; Rodriguez-Lopez AM; Munck JM; Haarberg HE; Sondak VK; Thompson NT; Azab M; Lyons JF; Smalley KSM; Wallis NG
Mol Cancer Ther; 2014 Dec; 13(12):2793-2804. PubMed ID: 25349308
[TBL] [Abstract][Full Text] [Related]
9. Oral lipid nanocomplex of BRD4 PROteolysis TArgeting Chimera and vemurafenib for drug-resistant malignant melanoma.
Saraswat A; Vartak R; Hegazy R; Fu Y; Rao TJR; Billack B; Patel K
Biomed Pharmacother; 2023 Dec; 168():115754. PubMed ID: 37871557
[TBL] [Abstract][Full Text] [Related]
10. BRAF Inhibitor Resistance Confers Increased Sensitivity to Mitotic Inhibitors.
Misek SA; Foda BM; Dexheimer TS; Akram M; Conrad SE; Schmidt JC; Neubig RR; Gallo KA
Front Oncol; 2022; 12():766794. PubMed ID: 35444937
[TBL] [Abstract][Full Text] [Related]
11. Kinase inhibitor library screening identifies synergistic drug combinations effective in sensitive and resistant melanoma cells.
Margue C; Philippidou D; Kozar I; Cesi G; Felten P; Kulms D; Letellier E; Haan C; Kreis S
J Exp Clin Cancer Res; 2019 Feb; 38(1):56. PubMed ID: 30728057
[TBL] [Abstract][Full Text] [Related]
12. HLA class I downregulation is associated with enhanced NK-cell killing of melanoma cells with acquired drug resistance to BRAF inhibitors.
Sottile R; Pangigadde PN; Tan T; Anichini A; Sabbatino F; Trecroci F; Favoino E; Orgiano L; Roberts J; Ferrone S; Kärre K; Colucci F; Carbone E
Eur J Immunol; 2016 Feb; 46(2):409-19. PubMed ID: 26564811
[TBL] [Abstract][Full Text] [Related]
13. Vemurafenib resistance reprograms melanoma cells towards glutamine dependence.
Hernandez-Davies JE; Tran TQ; Reid MA; Rosales KR; Lowman XH; Pan M; Moriceau G; Yang Y; Wu J; Lo RS; Kong M
J Transl Med; 2015 Jul; 13():210. PubMed ID: 26139106
[TBL] [Abstract][Full Text] [Related]
14. Vemurafenib Drives Epithelial-to-Mesenchymal Transition Gene Expression in BRAF Inhibitor‒Resistant BRAF
Jandova J; Wondrak GT
J Invest Dermatol; 2022 May; 142(5):1456-1465.e1. PubMed ID: 34687745
[TBL] [Abstract][Full Text] [Related]
15. MitoCur-1 induces ferroptosis to reverse vemurafenib resistance in melanoma through inhibition of USP14.
Li G; Zhou C; Wang L; Zheng Y; Zhou B; Li G; Ma Z; Sun P; Deng Y; Su L; Wang J; Cui H
Pigment Cell Melanoma Res; 2024 Mar; 37(2):316-328. PubMed ID: 37985430
[TBL] [Abstract][Full Text] [Related]
16. Silencing FLI or targeting CD13/ANPEP lead to dephosphorylation of EPHA2, a mediator of BRAF inhibitor resistance, and induce growth arrest or apoptosis in melanoma cells.
Azimi A; Tuominen R; Costa Svedman F; Caramuta S; Pernemalm M; Frostvik Stolt M; Kanter L; Kharaziha P; Lehtiö J; Hertzman Johansson C; Höiom V; Hansson J; Egyhazi Brage S
Cell Death Dis; 2017 Aug; 8(8):e3029. PubMed ID: 29048432
[TBL] [Abstract][Full Text] [Related]
17. miR-126-3p down-regulation contributes to dabrafenib acquired resistance in melanoma by up-regulating ADAM9 and VEGF-A.
Caporali S; Amaro A; Levati L; Alvino E; Lacal PM; Mastroeni S; Ruffini F; Bonmassar L; Antonini Cappellini GC; Felli N; Carè A; Pfeffer U; D'Atri S
J Exp Clin Cancer Res; 2019 Jun; 38(1):272. PubMed ID: 31227006
[TBL] [Abstract][Full Text] [Related]
18. Acquired resistance to BRAFi reverses senescence-like phenotype in mutant BRAF melanoma.
Krayem M; Najem A; Journe F; Morandini R; Sales F; Awada A; Ghanem GE
Oncotarget; 2018 Aug; 9(61):31888-31903. PubMed ID: 30159130
[TBL] [Abstract][Full Text] [Related]
19. Targeting Extracellular Matrix Remodeling Restores BRAF Inhibitor Sensitivity in BRAFi-resistant Melanoma.
Marusak C; Thakur V; Li Y; Freitas JT; Zmina PM; Thakur VS; Chang M; Gao M; Tan J; Xiao M; Lu Y; Mills GB; Flaherty K; Frederick DT; Miao B; Sullivan RJ; Moll T; Boland GM; Herlyn M; Zhang G; Bedogni B
Clin Cancer Res; 2020 Nov; 26(22):6039-6050. PubMed ID: 32820016
[TBL] [Abstract][Full Text] [Related]
20. Targeting the hedgehog transcription factors GLI1 and GLI2 restores sensitivity to vemurafenib-resistant human melanoma cells.
Faião-Flores F; Alves-Fernandes DK; Pennacchi PC; Sandri S; Vicente AL; Scapulatempo-Neto C; Vazquez VL; Reis RM; Chauhan J; Goding CR; Smalley KS; Maria-Engler SS
Oncogene; 2017 Mar; 36(13):1849-1861. PubMed ID: 27748762
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
